Press Room

More than 100 organizations representing millions of patients with serious health conditions and health care professionals sent a letter to Congress expressing their strong support for the Clinical Trial Modernization Act. Introduced in the House of Representatives in May 2025 by Reps. Raul Ruiz (D-CA) and August Pfluger (R-FL), the bipartisan legislation would help remove cost and geographic barriers to patient participation in clinical trials.

 A new ACS CAN study released in the Journal of the American Medical Association (JAMA) finds many patients aren’t made aware of the importance of pharmacogenomic (PGx) testing. A form of biomarker testing, PGx testing examines how variations in a patient’s inherited genes may impact how they respond to different drugs and can improve the effectiveness of treatment and reduce the risk of adverse drug reactions.

Today, the U.S. Senate Committee on Appropriations considered and approved its draft FY26 appropriations bill that includes increases for the National Institutes of Health (NIH) and increases for federal cancer research funding at the National Cancer Institute (NCI).

Today, the U.S. Senate voted to confirm Susan Monarez, PhD, as the next Director of the Centers for Disease Control and Prevention (CDC).

A new report from the nonpartisan Congressional Budget Office (CBO) finds that proposed cuts at the National Institutes of Health (NIH) could lower the number of new drugs that come to market in the next three decades.

Following U.S. House passage of the budget bill containing the most devastating cuts to Medicaid in history and changes to the ACA Marketplace that will make it more expensive and difficult to obtain and keep health insurance, ACS CAN expresses deep disappointment and urges Congress to extend the enhanced ACA tax credits.

Today, the U.S. Supreme Court issued its ruling in the case of Kennedy v. Braidwood Management.

A bill introduced earlier this year in the House and Senate now has the bipartisan support of the majority of the members in each chamber.

WASHINGTON, D.C. –  Today, the president released his final proposed budget for Fiscal Year 2026 which contains $4.531 billion for the National Cancer Institute (NCI).

Legislation aimed at increasing access to breast and cervical cancer screening was introduced today in the U.S. Senate. The bipartisan Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act would reauthorize the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for fiscal years 2026 through 2030.